William Blair Research Analysts Boost Earnings Estimates for Ovid Therapeutics Inc. (NASDAQ:OVID)

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities research analysts at William Blair raised their Q2 2025 earnings per share estimates for shares of Ovid Therapeutics in a research note issued on Monday, June 17th. William Blair analyst T. Lugo now forecasts that the company will post earnings per share of $0.12 for the quarter, up from their prior forecast of ($0.25). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.85) per share. William Blair also issued estimates for Ovid Therapeutics’ FY2025 earnings at ($0.62) EPS.

A number of other brokerages have also weighed in on OVID. Citigroup decreased their price target on shares of Ovid Therapeutics from $3.50 to $1.20 and set a “neutral” rating on the stock in a research note on Tuesday. BTIG Research decreased their price target on shares of Ovid Therapeutics from $11.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday. B. Riley decreased their price target on shares of Ovid Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday. Wedbush started coverage on shares of Ovid Therapeutics in a research note on Friday, April 5th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Oppenheimer lowered shares of Ovid Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.70.

Ovid Therapeutics Stock Performance

Shares of Ovid Therapeutics stock opened at $0.79 on Wednesday. The firm has a market capitalization of $55.89 million, a PE ratio of -1.08 and a beta of 0.58. Ovid Therapeutics has a twelve month low of $0.75 and a twelve month high of $4.14. The firm’s 50-day moving average price is $2.98 and its 200 day moving average price is $3.21. The company has a current ratio of 10.47, a quick ratio of 10.47 and a debt-to-equity ratio of 0.18.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.11 million. Ovid Therapeutics had a negative net margin of 10,691.14% and a negative return on equity of 53.62%.

Institutional Trading of Ovid Therapeutics

Institutional investors have recently made changes to their positions in the company. FFT Wealth Management LLC purchased a new stake in shares of Ovid Therapeutics during the 4th quarter valued at approximately $1,274,000. Assenagon Asset Management S.A. increased its holdings in Ovid Therapeutics by 45.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 114,265 shares of the company’s stock valued at $349,000 after purchasing an additional 35,786 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Ovid Therapeutics in the third quarter worth $61,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Ovid Therapeutics in the fourth quarter worth $26,000. Finally, SG Americas Securities LLC grew its stake in shares of Ovid Therapeutics by 52.7% in the fourth quarter. SG Americas Securities LLC now owns 39,792 shares of the company’s stock worth $128,000 after acquiring an additional 13,728 shares in the last quarter. Hedge funds and other institutional investors own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.